SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998; 16: 38323842.
  • 2
    Blade J. Transplantation for multiple myeloma: who, when, how often? Blood. 2003; 102: 34693478.
  • 3
    Salmon SE, Crowley JJ, Grogan TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1994; 12: 24052414.
  • 4
    Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984; 310: 13531356.
  • 5
    Friedenberg WR, Kyle RA, Knospe WH, et al. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol. 1991; 36: 171175.
  • 6
    Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990; 33: 8689.
  • 7
    Yang HH, Ma MH, Vescio RA, et al. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003; 21: 42394247.
  • 8
    Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 1993; 81: 22152222.
  • 9
    Benchimol S, Ling V. P-glycoprotein and tumor progression. J Natl Cancer Inst. 1994; 86: 814816.
  • 10
    Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlations with prior chemotherapy. Blood. 1993; 81: 490495.
  • 11
    Dalton WS, Grogan TM, Rybski JA, et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood. 1989; 73: 747752.
  • 12
    Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993; 81: 490495.
  • 13
    Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989; 7: 415424.
  • 14
    Bates S, Wilson W, Fojo T, et al. R-verapamil reverses drug resistance in some relapsed lymphoma patients. Anticancer Drugs. 1994; 5(Suppl 1): 72.
  • 15
    Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug resistance multiple myeloma by cyclosporin A. Lancet. 1992; 340: 255259.
  • 16
    Jonsson B, Nilsson K, Nygren P, et al. SDZ valspodar, a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs. 1992; 3: 641646.
  • 17
    Jaffrezou JP, Sikic BI, Laurent G. Cyclosporin A and cyclosporin A SDZ valspodar enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood. 1994; 83: 482489.
  • 18
    Sonneveld P, Marie JP, Lokhorst HM, et al. Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporin A and SDZ valspodar. Anticancer Drugs. 1994; 5(Suppl 1): 72.
  • 19
    Erlichman C, Moore M, Thiessen J, et al. A phase I trial of doxorubicin (DOX) and valspodar, a modulator of multidrug resistance (MDR). Anticancer Drugs. 1994; 5(Suppl 1): 42.
  • 20
    Giaccone G, Linn SC, Catimel G, et al. SDZ valspodar in combination with doxorubicin: a phase I and pharmacologic study in solid tumors. Anticancer Drugs. 1994; 5(Suppl 1): 42.
  • 21
    Fisher GA, Halsey J, Hausforff J, et al. A phase I study of paclitaxel (taxol) (T) in combination with SDZ valspodar, a potent modulator of multidrug resistance (MDR). Anticancer Drugs. 1994; 5(Suppl 1): 43.
  • 22
    Erlichman C, Moore MJ, De Angelis C, et al. The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ valspodar, in patients with advanced cancer. Anticancer Drugs. 1994; 5(Suppl 1): 44.
  • 23
    Gertz MA, Kalish LA, Kyle RA, et al. Phase III study comparing vincristine, doxorubicin (adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. Am J Clin Oncol. 1995; 18: 475480.
  • 24
    Dalton W, Greipp P, Greenberg P, et al. Phase I study of the chemosensitizer SDZ valspodar in combination with VAD chemotherapy to reverse multidrug resistance [abstract]. Blood. 1996; 88(Suppl 1): 662a.
  • 25
    Case DC Jr., Jain V, Stiff P, et al. Phase II study of PSC 833 (PSC) and VAD chemotherapy in patients with VAD-refractory multiple myeloma (MM). Blood. 1998; 92: 427a.
  • 26
    Dalton WS. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia. 1997; 11: 11661169.
  • 27
    Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 28
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 29
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972; 34: 187220.
  • 30
    East, v. 3.1. Cytel Software, Cambridge, MA, 2003.
  • 31
    Beketic-Oreskovic L, Duran GE, Chen G, et al. Decreased mutation rate for cellular resistance to doxorubicin and suppression of MDR1 gene activation by the cyclosporin A PSC 833. J Natl Cancer Inst. 1995; 87: 15931602.
  • 32
    Solary E, Drenou B, Campos L, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood. 2003; 102: 12021210.
  • 33
    Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator valspodar in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002; 100: 12241232.
  • 34
    Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004; 22: 10781086.
  • 35
    List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporin A modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001; 98: 3212:3220.
  • 36
    Leith CP, Chen IM, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR/efflux+ and MDR1+/efflux- cases. Blood. 1995; 86: 23292342.
  • 37
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997; 89: 33233329.
  • 38
    Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11: 265283.
  • 39
    Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004; 104: 19401952.